Medicines Co. (MDCO) Sells-Off with Alnylam (ALNY) Despite Providing Update

October 5, 2016 5:54 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Medicines Co. (NASDAQ: MDCO) is down 9.1% after-hours after Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.

Amid the news and sell-off, The Medicines Company (Nasdaq: MDCO) provided and update on its ORION-1 study and said no safety concerns were raised.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment